REGENXBIO 3Q 2026: Revenue $9.16M, EPS ($0.62) — 10-Q Summary
REGENXBIO reported Q3 2026 revenue of $9.16M, down 69.2% YoY, due to lower Zolgensma royalties. Net loss narrowed to $40.74M, aided by a $38M Sarepta settlement gain. Key developments include completed enrollment in Sura-vec trials and an FDA clinical hold on RGX-121.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue trends and a one‑time settlement, offering traders new information to adjust positions.
Market read
First‑time disclosure of a micro‑cap biotech's quarterly performance; relevant for biotech sector traders.
What to watch
Potential future FDA hold on RGX-121 may weigh more heavily than the current quarter's numbers.
Background
Regeneron Bio (RGNX) filed its Form 10‑Q for Q3 2026, reporting a sharp revenue decline due to Zolgensma royalty loss and a $38M settlement from Sarepta.
Ticker impact
Q3 2026 results show revenue down 69% YoY and a $38M settlement gain, marking the first public disclosure of the quarter's financials.
likely modest downside as investors weigh lower royalties against the settlement gain
The earnings release is the first report of a significant revenue drop and a one‑time settlement, both material to price.
Market effects
Highlights weakness in gene‑therapy royalty streams, may prompt sector peers to reassess royalty exposure.
Limited to US biotech investors; no broad regional effect.
Minimal global impact beyond niche gene‑therapy market.
Counterpoint
Settlement gain could be a catalyst for short‑term rally if investors focus on cash infusion.
Key entities
- CompanyRegeneron Bio
Biotech firm reporting Q3 2026 results.
- CompanySarepta Therapeutics
Counterparty in the $38M settlement.
